Get the straight facts
In September 2025, the FDA issued a series of warning letters to online sellers of compounded GLP-1 medications, and in February 2026, Novo Nordisk filed suit against Hims & Hers, alleging patent infringement through compounded semaglutide products
PSM with age, sex, race, and disease comorbidities was then conducted, yielding 162,253 matched patients for analysis
Table 2 The infiltrating situation of different subtypes of immune cells after the onset of ischemic stroke
Younger people (under 40) tend to lose weight faster, preserve muscle more easily, experience less loose skin, and achieve more dramatic before and after comparisons
The Bottom Line The Medicare GLP-1 Bridge launches in two days